Ana Rita Viana, Matteo Ripa, André Silva, Veronika Matello, Barbara Parolini
{"title":"新型黄斑扣环模型（NPB®）治疗近视牵引性黄斑病变的初步疗效和安全性结果。","authors":"Ana Rita Viana, Matteo Ripa, André Silva, Veronika Matello, Barbara Parolini","doi":"10.1177/11206721241310471","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe the efficacy and safety outcomes of NPB<sup>®</sup> macular buckle (MB) in myopic traction maculopathy (MTM).</p><p><strong>Methods: </strong>A monocentric, prospective cohort study of the naïve eyes who underwent MB surgery, alone or combined with <i>pars plana</i> vitrectomy (PPV) for MTM, using the new NPB<sup>®</sup> buckle, between December 2022 and June 2024. The anatomical results, postoperative complications, and MB ease of use were analyzed as the main outcomes. Secondary outcomes included changes in best-corrected visual acuity (BCVA), axial length (AL), and intraocular pressure (IOP).</p><p><strong>Results: </strong>Forty eyes of 39 patients were included, 34 (85%) were female. MB implantation alone was performed in 32 eyes (80%) and combined surgery in 8 (20%). At the final visit, 22 eyes (56,4%) \"resolved\" and 17 (43,6%) \"improved\" their retinal status, and 26 eyes (66,7%) \"resolved\", 8 (20,5%) \"improved\" and 5 (12,8%) \"unchanged\" their foveal status. Thirteen (32,5%) had repositioning surgery mainly due to MB decentration. Early complications (month 1) included diplopia in 3 eyes (7,5%) and elevation deficit without diplopia in 2 (5,0%). Late complications (month 6) involved mild buckle exposure in 3 cases (7,5%). No cases required MB removal or additional PPV. BCVA improved from 0,61 ± 0,35 to 0,49 ± 0,38 logMAR (<i>p</i> = 0,013), AL changed from 31,5 ± 2,2 to 30,0 ± 2,2 mm (<i>p</i> < 0,001), and IOP changed from 16,0 ± 2,7 to 14,5 ± 3,3 mmHg (<i>p</i> = 0,013), between the baseline and the final visit.</p><p><strong>Conclusions: </strong>The new MB model is an effective and safe technique for MTM treatment as a first-line strategy, alone or in combination with PPV.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721241310471"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preliminary efficacy and safety results of a new macular buckle model (NPB<sup>®</sup>) in myopic traction maculopathy.\",\"authors\":\"Ana Rita Viana, Matteo Ripa, André Silva, Veronika Matello, Barbara Parolini\",\"doi\":\"10.1177/11206721241310471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To describe the efficacy and safety outcomes of NPB<sup>®</sup> macular buckle (MB) in myopic traction maculopathy (MTM).</p><p><strong>Methods: </strong>A monocentric, prospective cohort study of the naïve eyes who underwent MB surgery, alone or combined with <i>pars plana</i> vitrectomy (PPV) for MTM, using the new NPB<sup>®</sup> buckle, between December 2022 and June 2024. The anatomical results, postoperative complications, and MB ease of use were analyzed as the main outcomes. Secondary outcomes included changes in best-corrected visual acuity (BCVA), axial length (AL), and intraocular pressure (IOP).</p><p><strong>Results: </strong>Forty eyes of 39 patients were included, 34 (85%) were female. MB implantation alone was performed in 32 eyes (80%) and combined surgery in 8 (20%). At the final visit, 22 eyes (56,4%) \\\"resolved\\\" and 17 (43,6%) \\\"improved\\\" their retinal status, and 26 eyes (66,7%) \\\"resolved\\\", 8 (20,5%) \\\"improved\\\" and 5 (12,8%) \\\"unchanged\\\" their foveal status. Thirteen (32,5%) had repositioning surgery mainly due to MB decentration. Early complications (month 1) included diplopia in 3 eyes (7,5%) and elevation deficit without diplopia in 2 (5,0%). Late complications (month 6) involved mild buckle exposure in 3 cases (7,5%). No cases required MB removal or additional PPV. BCVA improved from 0,61 ± 0,35 to 0,49 ± 0,38 logMAR (<i>p</i> = 0,013), AL changed from 31,5 ± 2,2 to 30,0 ± 2,2 mm (<i>p</i> < 0,001), and IOP changed from 16,0 ± 2,7 to 14,5 ± 3,3 mmHg (<i>p</i> = 0,013), between the baseline and the final visit.</p><p><strong>Conclusions: </strong>The new MB model is an effective and safe technique for MTM treatment as a first-line strategy, alone or in combination with PPV.</p>\",\"PeriodicalId\":12000,\"journal\":{\"name\":\"European Journal of Ophthalmology\",\"volume\":\" \",\"pages\":\"11206721241310471\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/11206721241310471\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241310471","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：评价NPB®黄斑扣环（MB）治疗近视牵引性黄斑病变（MTM）的疗效和安全性。方法：在2022年12月至2024年6月期间，使用新型NPB®扣环，对接受MB手术单独或联合计划部玻璃体切除术（PPV）治疗MTM的naïve眼睛进行单中心前瞻性队列研究。以解剖结果、术后并发症和MB的易用性为主要观察指标。次要结果包括最佳矫正视力（BCVA）、眼轴长度（AL）和眼内压（IOP）的变化。结果：39例患者40只眼，其中女性34只（85%）。单独行MB植入术32眼（80%），联合手术8眼（20%）。在最后一次访问时，22只眼睛（56.4%）“解决”和“17”（43.6%）“改善”了他们的视网膜状态，26只眼睛（66.7%）“已解决”，8 （20.5%）“改善”和“5”（12.8%）“不变”他们的中央凹状态。13例（32.5%）手术复位，主要原因是MB脱位。早期并发症（第1个月）包括复视3眼（7.5%）和无复视的仰角缺损2眼（5.0%）。晚期并发症（第6个月）包括3例轻度扣环暴露（7.5%）。没有病例需要切除MB或额外的PPV。基线和最后一次访问期间，BCVA从0.61±0.35 mm改善到0.49±0.38 mm (p = 0.013)， AL从31.5±2.2 mm改善到30.0±2.2 mm （p = 0.013）。结论：无论是单独治疗还是联合PPV治疗，新的MB模型都是一种有效且安全的MTM一线治疗方法。
Preliminary efficacy and safety results of a new macular buckle model (NPB®) in myopic traction maculopathy.
Purpose: To describe the efficacy and safety outcomes of NPB® macular buckle (MB) in myopic traction maculopathy (MTM).
Methods: A monocentric, prospective cohort study of the naïve eyes who underwent MB surgery, alone or combined with pars plana vitrectomy (PPV) for MTM, using the new NPB® buckle, between December 2022 and June 2024. The anatomical results, postoperative complications, and MB ease of use were analyzed as the main outcomes. Secondary outcomes included changes in best-corrected visual acuity (BCVA), axial length (AL), and intraocular pressure (IOP).
Results: Forty eyes of 39 patients were included, 34 (85%) were female. MB implantation alone was performed in 32 eyes (80%) and combined surgery in 8 (20%). At the final visit, 22 eyes (56,4%) "resolved" and 17 (43,6%) "improved" their retinal status, and 26 eyes (66,7%) "resolved", 8 (20,5%) "improved" and 5 (12,8%) "unchanged" their foveal status. Thirteen (32,5%) had repositioning surgery mainly due to MB decentration. Early complications (month 1) included diplopia in 3 eyes (7,5%) and elevation deficit without diplopia in 2 (5,0%). Late complications (month 6) involved mild buckle exposure in 3 cases (7,5%). No cases required MB removal or additional PPV. BCVA improved from 0,61 ± 0,35 to 0,49 ± 0,38 logMAR (p = 0,013), AL changed from 31,5 ± 2,2 to 30,0 ± 2,2 mm (p < 0,001), and IOP changed from 16,0 ± 2,7 to 14,5 ± 3,3 mmHg (p = 0,013), between the baseline and the final visit.
Conclusions: The new MB model is an effective and safe technique for MTM treatment as a first-line strategy, alone or in combination with PPV.
期刊介绍：
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
